Publications by authors named "Shayan N Nouri"
Article Synopsis
- The study investigates the use of off-label peripheral drug-coated balloons (P-DCB) for treating coronary in-stent restenosis (ISR) in patients, as dedicated drug-coated balloons are not available in the U.S.
- Data from 31 patients treated at a high-volume center showed that a significant percentage had recurrent ISR and high-grade symptoms, with most lesions found in native coronary arteries.
- Follow-up indicated that while no post-procedural heart attacks occurred, there was a notable recurrence rate of ISR, with only 44.7% of patients free from further issues at the time of follow-up.
Article Synopsis
- The study investigates the link between modified body mass index (mBMI) and outcomes following treatment for pulmonary embolism (PE) in patients categorized as intermediate or high risk.
- Results showed that lower mBMI is associated with higher rates of in-hospital mortality and bleeding, indicating its potential as a frailty indicator.
- The findings suggest that addressing low mBMI may be crucial for improving clinical outcomes in PE patients, highlighting the need for further research in this area.
Article Synopsis
- * Conducted from February to June 2020, it analyzed data from 2,626 hospitalized patients, with 951 being prior users of statins.
- * Results indicated that statin users had significantly lower odds of dying within 30 days of hospitalization compared to non-users, suggesting a protective effect of statins in COVID-19 cases (OR 0.47).
Objectives: To describe hemodynamic efficacy and clinical outcomes of Impella percutaneous left ventricular assist device (pLVAD) in patients with cardiogenic shock (CS).
Background: Percutaneous LVADs are increasingly used in CS management. However, device-related outcomes and optimal utilization remain active areas of investigation.
Article Synopsis
- - The study examines the impact of prior statin use on in-hospital mortality in COVID-19 patients, noting that COVID-19 can cause severe inflammatory responses leading to complications like ARDS and other organ damage.
- - Researchers analyzed data from 2,626 patients admitted with COVID-19 between February 1 and May 12, 2020, finding that 951 (36.2%) were statin users prior to hospitalization.
- - Results showed that statin users had significantly lower odds of in-hospital mortality compared to non-statin users, prompting the need for further randomized clinical trials to confirm the benefits of statins in COVID-19 treatment.
Article Synopsis
- COVID-19 is caused by the SARS-CoV-2 virus, and there's growing concern about thrombotic events (blood clots) contributing to serious health issues in infected patients.
- The Global COVID-19 Thrombosis Collaborative Group discusses novel dosing strategies for common antithrombotic medications, particularly heparin, and explores the potential of other less common drugs for preventing COVID-19-related blood clots.
- The article emphasizes the need for further research, including clinical trials, to evaluate the safety and effectiveness of various treatments, and considers the role of immunomodulators with potential antithrombotic benefits.